ICE – What Canadians Should Expect
ICE – What Canadians Should Expect – With just one week away from recreational marijuana becoming legal in Canada, we’re continuing to break down what it means for people crossing the border.
On Wednesday morning, Chief Customs and Border Protection Officer Aaron Bowker came to Wake Up! to discuss this.
U.S. Customs and Border Protection issued a clarification to a policy many feared would prevent Canadians who work or invest in marijuana businesses from entering the country.
- “A Canadian citizen working in or facilitating the proliferation of the legal marijuana industry in Canada, coming to the U.S. for reasons unrelated to the marijuana industry will generally be admissible to the U.S. however, if a traveler is found to be coming to the U.S. for reason related to the marijuana industry, they may be deemed inadmissible.”
New government data shows that 90% of Canadians live within 10km of a liquor store. Meanwhile, only 35% will live within the same distance of a planned marijuana store upon next week’s legalization launch.
Specifically, the U.S. Food and Drug Administration (FDA) is asking for public comments about the “abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use” of cannabis and several other substances now under international review.
Under current U.S. federal law as well as global drug policy agreements, marijuana is classified in the most restrictive category of Schedule I. At home, that means it is considered illegal and not available for prescription, while research on its potential benefits is heavily restricted. Cannabis’s international status means that nations who are signatories of drug control treaties are not supposed to legalize it, though that hasn’t stopped Canada and Uruguay from doing so.
Public comments on marijuana’s effects and legal status “will be considered in preparing a response from the United States to the World Health Organization (WHO) regarding the abuse liability and diversion of these drugs,” Leslie Kux, FDA’s associate commissioner for policy, wrote in a Federal Register filing published on Wednesday. “WHO will use this information to consider whether to recommend that certain international restrictions be placed on these drugs.”